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Abstract
Objectives: It has been shown that socioeconomic status (SES) is associated with adherence to
treatment of patients with several chronic diseases. However, there is a controversy regarding the
impact of SES on adherence among patients with the human immunodeficiency virus (HIV) infection
or acquired immunodeficiency syndrome (AIDS). Thus, we sought to perform a systematic review
of the evidence regarding the association of SES with adherence to treatment of patients with HIV/
AIDS.
Methods: We searched the PubMed database to identify studies concerning SES and HIV/AIDS
and collected data regarding the association between various determinants of SES (income,
education, occupation) and adherence.
Findings: We initially identified 116 potentially relevant articles and reviewed in detail 17 original
studies, which contained data that were helpful in evaluating the association between SES and
adherence to treatment of patients with HIV/AIDS. No original research study has specifically
focused on the possible association between SES and adherence to treatment of patients with HIV/
AIDS. Among the reviewed studies that examined the impact of income and education on
adherence to antiretroviral treatment, only half and less than a third, respectively, found a
statistically significant association between these main determinants of SES and adherence of
patients infected with HIV/AIDS.
Conclusion: Our systematic review of the available evidence does not provide conclusive support
for existence of a clear association between SES and adherence among patients infected with HIV/
AIDS. There seemed to be a positive trend among components of SES (income, education,
occupation) and adherence to antiretroviral treatment in many of the reviewed studies, however
most of the studies did not establish a statistically significant association between determinants of
SES and adherence.
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Introduction
Suboptimal adherence to medical treatment with antiret-
roviral agents has been associated with increased morbid-
ity and mortality, potential transmission of drug-resistant
virus, drug resistance, and failure to achieve viral suppres-
sion [1-4]. Adherence to treatment in patients infected
with the human immunodeficiency virus (HIV) or
acquired immunodeficiency syndrome (AIDS) is influ-
enced by factors associated with the patient, the disease,
the patient-physician relationship, and the therapy [1-5].
Patient related determinants are socioeconomic status
(SES), demographic, psychological, cognitive and behav-
ioral characteristics [1,6-9].
It is suggested that SES is consistently associated with
higher adherence to medical treatment in patients suffer-
ing from chronic diseases, such as asthma, diabetes, and
post-myocardial infarction [1,7,10-12]. Suggested path-
ways in which SES might be associated with adherence, as
well as morbidity and mortality, include education's effect
on shaping a financially stable future, and on acquiring
health literacy and knowledge to use health resources,
while income plays a big part in obtaining better housing
conditions, recreational facilities and better health care
[13]. Moreover, occupation in terms of employment sta-
tus affects the ongoing stress of the patients and their abil-
ity to use health care facilities, while occupational status
can be reflected on the physical (possible environmental
exposure to damaging agents) and psychosocial (lack of
control over one's daily program) aspects of a low-SES
patient's life [13]. All of these parameters influence acces-
sibility to appropriate treatment and the patients' will to
comply.
Although adherence is higher in patients with HIV/AIDS
than in other chronic diseases (cardiovascular, infectious
and pulmonary diseases) [7,14], it is not clear whether
SES is associated with higher adherence to HIV therapy. A
possible association between SES and adherence to treat-
ment among HIV patients may have an impact on the suc-
cess of their treatment, mainly because the knowledge of
such an association may help the treating physicians iden-
tify patients who are less likely to adhere to treatment and
thus, make more effort to influence the patient's adher-
ence to treatment. In such a fashion, SES could affect the
patient's quality of life, the social life of the patients and
their families, the patient-physician relationship, and cre-
ate a need for changes in matters of the public health sys-
tem [1-4]. Subsequently, the effect of SES on adherence
among HIV infected patients is considered a controversial
issue [1,15,16]. Following the lead of other chronic dis-
eases (diabetes, asthma, coronary disease), we hypothe-
sized that a possible positive association between level of
SES and level of adherence to antiretroviral treatment
could exist and, thus, would be presented in our reviewed
studies.
It is noteworthy that despite the fact that SES is a com-
monly used term, it is rather difficult to define and meas-
ure it [17]. According to "The New Dictionary of Cultural
Literacy"(3d Edition 2002), SES depends on a combina-
tion of variables including occupation, education,
income, and place of residence [18]. In this review, we
attempted to synthesize the data regarding the association
between SES and adherence to treatment of patients with
HIV/AIDS, using information reported on major determi-
nants of SES, namely income, education, and occupation.
Methods
Literature search
Two independent reviewers performed the literature
search, study selection, and data extraction. Disagree-
ments between these reviewers were resolved in meetings
of all authors. We performed a systematic search of the lit-
erature to identify reviews and original studies that
reported data regarding the impact of SES on adherence in
HIV/AIDS patients. The relevant studies were identified by
the use of the PubMed database (articles written in Eng-
lish), published until 2006. In addition, we performed
additional searches of various Internet resources on HIV/
AIDS [2,9,17,18]. Also, we searched the relevant articles
identified from the list of references of the initially
retrieved papers. We used 3 different search strategies
using the following key words: 1. Socioeconomic status
AND (HIV OR AIDS) AND (compliance OR adherence),
2. (Compliance OR adherence) AND (HIV OR AIDS)
AND determinants, 3. (AIDS OR HIV) AND (compliance
OR adherence) AND education AND income.
Study selection
The inclusion and exclusion criteria used for the studies
reviewed, were set before the literature search. Studies
included in our study concerned only individual HIV-
infected adult patients and their adherence to antiretrovi-
ral treatment. Reviews and editorials were not included in
our systematic review. We excluded studies focused on
HIV prevention, quality of life, attitude, and health status
of patients. We also excluded studies, which compared the
outcomes of treatment with different antiretroviral drugs
without reporting specific data for the SES of the studied
patients. Additionally, we excluded studies that focused
on HIV-infected illicit drug users, as such users have spe-
cific psychosocial characteristics [19] and are in need of a
special approach in order to adhere to medical treatment
[20], a fact that differentiates them from the general pop-
ulation.Retrovirology 2008, 5:13 http://www.retrovirology.com/content/5/1/13
Page 3 of 12
(page number not for citation purposes)
Data extraction
From the studies that were included in our systematic
review we extracted data regarding the date of publication,
the setting of the study, the patient population, details of
the medical treatment (monotherapy, Highly Active Anti-
Retroviral Therapy – HAART), data relevant to SES, the
measure of adherence, the overall adherence and findings
regarding the association between major determinants of
SES and adherence. In this study we assessed three param-
eters as major factors contributing to SES, namely,
income, education, and occupation, and we examined
their association with adherence to treatment of HIV
infected patients.
Findings
In Figure 1 we present the various steps in the study selec-
tion process. There were 116 potentially relevant studies
from which we further reviewed 17 studies with original
data. In Table 1 we present the characteristics of the 17
studies that were included in our systematic review. The
year of publication of the studies ranged from 1991 to
2005. There was considerable variability among studies
regarding the setting and the patient populations includ-
ing different countries and different average socioeco-
nomic and cultural background, respectively. In some
studies the sample size of the population was small
[4,21,22]. We reviewed 9 longitudinal [3,4,14,16,21-25]
and 8 cross-sectional [15,26-32] studies, while the average
patient number of the total 17 studies was 411 patients
per study (ranging from 40 to 2267, depending on the
study setting). The populations had previously been intro-
duced to HAART in at least 12 of the reviewed studies
[4,14-16,23-26,28-30,32]. Details regarding the antiretro-
viral treatment, such as the specific regimens used or the
percentage of the population using them, were not
reported in several studies [3,16,23,27,30,31]. Moreover
studies varied in the measurement of adherence [pills per
dose, doses per day, days of treatment per week(s), respect
of the exact time schedule of obtaining the medications,
etc] and used different cutoff point of adherence (from
80% to 100% of dosage) in order to dichotomize the
patients between adherent and non-adherent.
We did not identify a study focused directly on the associ-
ation between SES or its main determinants analyzed as a
group and adherence. In Table 2 we present the available
reported data regarding factors contributing to SES, the
method with which adherence to antiretroviral treatment
was measured, and the overall adherence. In 11 out of 17
studies included in our review, self-report by the patients
was the main measure of adherence to treatment
[15,16,23-31]. The main parameters affecting SES
(income, education, occupation) were not examined as a
group comprising SES, but were rather regarded as demo-
graphic characteristics in most reviewed studies
[14,24,25,28-31], therefore many studies lacked data con-
cerning some of the parameters. There were insufficient
data regarding income in 6 [15,16,21,24,30,32] and edu-
cational level in also 6 [15,16,24,27,28,31] of the 17
reviewed studies, respectively (some of the studies had
data regarding income but not for education and others
the reverse). Employment status was assessed in 9 studies
[3,4,14,15,22,23,25,26,32], however no data were given
on occupational status or working position. Health liter-
acy was assessed in 1 study [29]. We considered this char-
acteristic closely connected to educational level, therefore
we included it as part of education in the presentation of
the data.
In Table 3 we present the main findings regarding the
analysis of the association of the various components of
SES and adherence. Income, level of education, and
employment status were statistically significantly associ-
ated with the level of adherence in 7
[14,21,23,25,28,30,31], 5 [14,16,24,29,30], and 1 [15]
original study, respectively (out of 17 studies reviewed);
most significant findings refer to a positive association
between levels of SES components and levels of adherence
to antiretroviral treatment, although two of the reviewed
studies suggest an adverse association between education
[30] or having a busy workload [15], respectively, and
adherence. However, the aforementioned SES determi-
nants were not found to be statistically significantly asso-
ciated with adherence in 7 [3,4,22,24,26,27,29], 8
[3,4,21,22,25-27,32], and 7 [3,4,14,22,24,25,32] other
studies that examined such an association, respectively.
Discussion
In this systematic review we found that SES was not con-
sistently associated with adherence to treatment among
HIV infected patients. Since there was no study directly
examining the association between SES and adherence in
patients with HIV/AIDS, we evaluated the available data
regarding the possible association between the major sep-
arate determinants of SES (income, education, occupa-
tion) and adherence. Although someone would have
expected a clear association between SES and adherence to
treatment based on data from studies on patients with
chronic diseases other than HIV/AIDS infection, the evi-
dence from the available studies does not fully support
the existence of such an association in this patient popu-
lation. However, a positive trend of association between
levels of various SES components and levels of adherence
to antiretroviral treatment is present among many of the
studies.
By taking a close look at the data presented, it is notewor-
thy that among the reviewed studies that examined some
of the main components of SES, most did not find a sta-
tistically significant association between these factors andR
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Table 1: Design characteristics of the studies included in our systematic review
First author, Year of 
publication 
[Reference number]
Setting Type of Study Patient Population Type of Medication (*)
Laniece I., 2003 [23] Senegal, Dakar, 3 health structures Prospective cohort study (2 years) 158 HIV(+) adults, enrolling into ISAARV (Senegalese ARV 
Access Initiative)
HAART, mainly
Mohammed H., 2004 [26] USA, Non-urban Louisiana, 8 HIV 
outpatient clinics
Retrospective study (clinic survey) (30 
months)
273 HIV(+) adults, using HAART HAART
Eldred L.J., 1998 [27] USA, Baltimore, Johns Hopkins 
Hospital, HIV Outpatient Clinic
Retrospective study (clinic survey) (9 
months)
244 HIV(+) adults, Medicaid-insured, at least one previous clinic 
visit in previous 6 months + prescription of antiretroviral therapy 
for at least 6 months
Antiretroviral 
monotherapy, mainly
Kleeberger C.A., 2004 [24] USA, Multicenter (4 centres in 
Baltimore, Chicago, Pittsburgh, Los 
Angeles)
Prospective cohort study (2 years) 597 HIV(+) homosexual men, using HAART + participating in 
MACS (Multicenter AIDS Cohort Study), between patients' 30th 
and 33rd visit [only 486 provided needed data on follow-up]
HAART
Peretti-Watel P., 2005 [28] France, 102 hospital departments 
delivering HIV care
Cross-sectional study (national survey) (1 
year)
1809 HIV(+) adults (homosexual men, heterosexual men, and 
heterosexual women), French speaking, diagnosed as HIV(+) for 
at least 12 months, living in France for at least 6 months + 
sexually active during the prior 12 months
HAART
Fong O.W., 2003 [15] Hong Kong, Integrated Treatment 
Centre of the Department of Health
Retrospective study (1 year) 161 HIV(+) adults, Chinese in origin + treated with HAART for 
at least 12 months (at the end of 2000)
HAART
Kleeberger C.A., 2001 [25] USA, Multicenter (4 centres in 
Baltimore, Chicago, Pittsburgh, Los 
Angeles)
Prospective cohort study (6 months) 539 HIV(+) homosexual men, during their 30th visit to MACS HAART, mainly
Goldman D.P., 2002 [16] USA Retrospective analysis of prospective 
study, (2 years)
2864 HIV(+) adults, participating in HCSUS (HIV Cost and 
Services Utilization Study [only 2267 provided needed data on 
last follow-up]
HAART, mainly
Golin C.E., 2002 [14] USA, North Carolina, County Hospital 
HIV Clinic
Prospective cohort study (1 year) 117 HIV(+) adults, English or Spanish speaking + newly initiating 
HAART (PI or NNRTI)
HAART
Singh N., 1999 [3] USA, 3 Medical Centres, HIV Clinics Prospective cohort study (6 months) 123 HIV (+) adults, followed in any of the clinics Antiretroviral treatment, 
not specified
Kalichman S.C., 1999 [29] USA, Georgia, Atlanta, community area Community-based study (Regional 
survey)
184 HIV(+) adults, receiving triple-drug combination HAART
Weiser S., 2003 [30] Botswana, 3 private clinics (2 in 
Gabarone, 1 in Francistown)
Cross-sectional study (Clinic survey) (7 
months)
109 HIV (+) adults Antiretroviral treatment 
(HAART 31%)
Morse E.V., 1991 [21] USA, Louisiana, New Orleans Nurse-based survey (6 months) 40 HIV (+) adults, asymptomatic + participating in ACTG (AIDS 
Clinical Trials Group) [the 20 most and the 20 least adherent 
patients]
ZDV or placebo
Gebo K.A., 2003 [31] USA, Baltimore, Johns Hopkins 
University, HIV Clinic
Cross-sectional study (Clinic survey) (8 
months)
196 HIV (+) adults, enrolling in the HIV Clinic + taking at least 1 
antiretroviral medication
Antiretroviral treatment, 
not specified
Duong M., 2001 [32] France, Dijon Hospital AIDS day-care 
Unit
Prospective cross-sectional study (5 
months)
149 HIV (+) adults, receiving drug regimens including 2 
nucleoside analogues + 1 or more PIs
HAART
Ickovics J.R, 2002 [4] USA, Multicenter (21 collaborating 
units)
Prospective analysis of Randomised 
Controlled Trial (24 weeks)
93 HIV (+) adults, participating in ACTG (AIDS Clinical Trial 
Group) protocol 307
dT4+ DLV+IDV, 
ZDV+3TC+IDV, 
ZDV+DLV+IDV
Singh N., 1996 [22] USA, Pittsburgh VA Medical Center Prospective study (12 months) 46 HIV (+) male adults ZDV only (78%), ZDV + ddI 
(13%), ddI only (8%)
(*) Abbreviations in medication: HAART = highly active antiretroviral treatment, ZDV = zidovudine, dT4 = stavudine, DLV = delaviridine, IDV = indinavir, 3TC = lamivudineRetrovirology 2008, 5:13 http://www.retrovirology.com/content/5/1/13
Page 5 of 12
(page number not for citation purposes)
Flow diagram of reviewed studies Figure 1
Flow diagram of reviewed studies. Flow diagram of all reviewed studies, showing how we ended up with the 17 original 
studies we further analyzed.
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Table 2: Socioeconomic characteristics and adherence measurement in the studies included in our review.
First author, Year of 
publication 
[Reference number]
SES Adherence
Income Education Employment Measure of adherence Adherence
Laniece I., 2003 [23] Median monthly income: 15,000 
FCFA (about 20 US$) [80 (50.6%) 
participate in clinical trials and are 
free of charge]
Without school education: 
50 (32%)
Not in paid 
employment: 65 (41%)
Self-reported number of tablets taken + number 
of tablets prescribed (by dispensing pharmacist), 
monthly. Mean and optimal (= 100% of dosage) 
adherence measured.
69% of self-reports optimal. 91% mean 
overall adherence self-reported.
Mohammed H., 2004 [26] Monthly income: 0–999 US$: 220 
(80.6%) >1,000 US$: 41 (15.0%) 
Missing 12 (4.4%)
High school or less: 184 
(67.4%) Greater than high 
school: 79 (28.9%) Missing: 
10 (3.7%)
Employed: 59 (21.6%) 
Unemployed: 205 
(75.1%) Missing: 9 
(3.3%)
Self-report of missing doses in previous week 
(interview with patient). Optimal (= 100% of 
dosage) adherence measured.
65.6% of self-reports optimal
Eldred L.J., 1998 [27] Annual income: <$10,000 US$: 
220 (91.3%) >$10,000 US$: 21 
(8.7%) [All patients were insured 
and could cover treatment cost]
Grouped proportions not 
reported
No given data Self-report of missing doses in previous week, 
self-report of missing days of treatment in 
previous 2 weeks (interview with patient) + 
examining medical record data of the 
Outpatient Clinic. Optimal (≥ 80% of doses and 
days) adherence measured.
Self-report vs. medical records: 60.4% 
vs. 55.8% optimal in previous week + 
74.3% vs. 67.3% optimal in previous 2 
weeks.
Kleeberger C.A., 2004 
[24]
Grouped proportions not 
reported
Grouped proportions not 
reported
Grouped proportions 
not reported
Self-report of missing doses/pills in 4 previous 
days or not having a typical pattern in 
medication, every 6 months. Consecutive visit-
pairs (1,128) were studied for decrease/increase 
in adherence from/to optimal to/from 
suboptimal. Optimal (= 100% of dosage) 
adherence measured.
88.7% of visit-pairs remained in 
optimal adherence. 71.5% of visit-pairs 
that reported suboptimal adherence in 
starting visit, increased to optimal in 
next visit. 38.8% of patients with 4 
total visits reported suboptimal 
adherence, at least at one visit.
Peretti-Watel P., 2005 
[28]
Financial situation of household 
satisfying: 1320 (73.0%) Housing 
conditions satisfying/acceptable: 
1566 (86.6%) Food privation in 
household: 197 (10.9%)
No given data No given data Self-report of missing doses or not respecting 
time schedule, in previous week (interview with 
patient). Optimal (= 100% of dosage/timetable) 
adherence measured.
58% of self-reports optimal
Fong O.W., 2003 [15] No given data No given data Busy workload: 16 
(9.9%)
Self-report of missing doses since last follow-up, 
at each clinic visit Optimal (= 100% of dosage) 
adherence measured. Suboptimal adherence 
graded and measured.
80.7% of self-reports optimal. 15.5% of 
self-reports suboptimal but high grade 
of adherence (>95%). 1.9% of self-
reports low grade of adherence 
(<90%).
Kleeberger C.A., 2001 
[25]
Annual income: >50,000 US$: 165 
(33.0%) <50,000 US$ 335: (67.0%)
College or more: 300 
(56.3%) Less than college: 
233 (43.7%)
Not full time: 178 
(39.4%) Full time: 274 
(60.6%)
Self-report of missing doses/pills in 4 previous 
days or not having a typical pattern in 
medication. Optimal (= 100% of dosage) 
adherence measured.
77.7% of self-reports optimal
Goldman D.P., 2002 [16] No given data Grouped proportions not 
reported
No given data Self-report of missing doses/days of medication 
in previous week, on every follow-up. Optimal 
(= 100% of dosage) adherence measured.
Overall adherence not reported. 
37.1%–57.3% optimal adherence to 
HAART, depending on years of 
schooling.
Golin C.E., 2002 [14] Annual Income: <10,000 US$: 74 
(63%) >10,000 US$: 43 (34%)
Less than high school: 41 
(35%) High school or more: 
76 (65%)
Working: 35 (30%) Not 
working: 82 (70%)
Evaluation of electronic medication bottle caps 
(MEMS) + pill count, every 4 weeks, and self-
report of missing doses in the previous week, 
on 4 of the visits (interview with the patient). 
Mean and optimal (≥ 95% of dosage) adherence 
measured.
4% optimal adherence reported. 71% 
mean overall adherence reported.
Singh N., 1999 [3] Monthly income: <500$: 22 (18%) 
500–1,000$: 42 (34%) 
1,000–1,500$: 27 (22%) >1,500$: 
27 (22%) Not stated: 5 (4.1%)
Grade school: 5(4%) 
Technical: 6(5%) High 
school: 51(42%) College: 
53(42%) Postgraduate: 
8(7%)
Employed: 58 (47%) 
Unemployed: 65 (53%)
Refill methodology, monthly (all patients filled 
prescriptions exclusively through site 
pharmacy). Optimal (≥ 90% of dosage) 
adherence measured.
82% optimal adherence reported.R
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Kalichman S.C., 1999 [29] <10,000 US$: 114 (62%) >10,000 
US$: 70 (38%)
<12 years: 27 (14.7%) >12 
years: 157 (85.3%) Lower 
health literacy TOFHLA: 
29(15.8%)
No given data Self-report of missing doses in previous 2 days 
(interview with patient). Mean and optimal (= 
100% of dosage) adherence measured.
80.4% of self-reports optimal. 92.6% 
mean overall adherence self-reported.
Weiser S., 2003 [30] No given data Primary: 14 (13%) 
Secondary: 45 (41%) Post-
secondary: 50 (46%)
No given data Self-report of missing doses in previous day/
week/month/year (interview with patient). 
Optimal (≥ 95%) adherence measured.
54% self-reports were optimal. An 
additional 29% of self-reports would 
be optimal if days of treatment hadn't 
been missed on financial grounds ('gaps 
in treatment').
Morse E.V., 1991 [21] Proportion of patients receiving 
economic support by 'significant 
other' not reported
Less than high school: 2 
(5.3%) High school 
graduates: 12 (31.6%) 
College: 10 (26.3%) College 
degree: 11 (29%) 
Professional/graduate 
degree: 3 (7.9%)
No given data Nurse-based measurement of the Clinical Trial 
participants: 20 most adherent and 20 least 
adherent participants.
Not applicable.
Gebo K.A., 2003 [31] Running out of money for life 
essentials in the previous 90 days: 
104 (53%)
No given data No given data Self-report of missing doses in the previous 2 
weeks (interview with patient). Mean and 
optimal (≥ 90% of dosage) adherence measured.
71% of self-reports optimal. 80% mean 
overall adherence self-reported.
Duong M., 2001 [32] No given data Grade school: 13 (9%) High 
school: 28 (19%) Technical 
school: 68 (46%) College: 
40 (27%)
Employed: 80 (54%) 
Unemployed: 68 (46%)
Biological markers: HIV RNA undetectable or 
lower than criteria + PI plasma levels above 
reference. Optimal (= virologic response + 
adequate PI levels) adherence measured.
89% optimal adherence reported.
Ickovics J.R, 2002 [4] Average yearly income: <$19,000: 
47 (50.5%) >$20,000: 46 (49.5%)
High school or less: 
39(42%) College/technical 
school or more: 54(56%)
Work for pay outside 
home: Yes: 67 (72%) 
No: 21 (23%) Missing: 5 
(5%)
Self-report of number of pills skipped in 
previous 4 days (interview with the patient at 
baseline, week 2, week 4 and every 4 weeks 
thereafter through to week 24). Optimal (≥ 95% 
of dosage) adherence was measured.
63% of self-reports optimal.
Singh N., 1996 [22] Median monthly income: 500–749 
US$ No income: 5 (11%) >1,500 
US$: 7 (15%) [All patients 
received treatment free of charge]
Less than high school: 10 
(22%) High school: 9 (19%) 
College: 13 (28%) Technical 
education: 13 (28%) 
Postgraduate: 1 (2%)
Employed: 15 (33%) Refill methodology, monthly (all patients filled 
prescriptions exclusively through site 
pharmacy). Optimal (≥ 80% of dosage) 
adherence was measured.
63% optimal adherence reported.
Table 2: Socioeconomic characteristics and adherence measurement in the studies included in our review. (Continued)Retrovirology 2008, 5:13 http://www.retrovirology.com/content/5/1/13
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adherence to antiretroviral treatment. It should be empha-
sized that a statistically significant association between
income and education, two main determinants of SES,
and adherence was found in only half and less than a third
of the studies that examined income and education,
respectively.
The existence of a possible association between income
and adherence to treatment in HIV/AIDS patients was
examined in 14 of the reviewed studies. Among the 7
studies in which income was found to be significantly
associated with adherence, 4 concluded that the cost of
antiretroviral treatment and/or poor living conditions
were factors preventing patients from complying with
treatment. If this financial obstacle was overcome, adher-
ence was expected to reach considerably higher levels
[23,28,30,31]. In the remaining 3 studies, among patients
having the economic ability to receive their medication,
there was an association between the annual income and
adherence [14,21,25]. It is presumed by the authors of
one of the studies that patients with a higher level of
income differ to those of lower/middle income, in terms
Table 3: Association between the main components of the socioeconomic status (SES) and adherence to treatment in HIV infected 
patients.
First author, Year of 
publication 
[Reference Number]
Income Education Employment Main Findings
Laniece I., 2003 [23] S.S.* -* - Mean adherence among patients who were free of charge was higher 
than those participating in cost, in a statistically significant level, during 
17 months of the study. Mean adherence among patients participating 
in cost + receiving D4T/ddI/IDV increased when cost participation 
decreased (during second year of study).
Mohammed H., 2004 [26] N.S.* N.S. - No SES components were significantly associated with adherence.
Eldred L.J., 1998 [27] N.S. N.S. - No SES components were significantly associated with adherence.
Kleeberger C.A., 2004 [24] N.S. S.S. N.S. Having less than a college education was an independent factor 
significantly associated with lowering adherence from optimal to 
suboptimal between two consecutive visits of the patient.
Peretti-Watel P., 2005 [28] S.S. - - Poor living conditions (except for food privation among homosexual 
men) were identified as an independent factor significantly associated 
with suboptimal adherence in all of the patients' subgroups.
Fong O.W., 2003 [15] - - S.S. Having a busy workload was found as an independent factor 
significantly associated with lower level of adherence.
Kleeberger C.A., 2001 [25] S.S. N.S. N.S. Annual income <50,000 US$ was identified as an independent factor 
significantly associated with lower level of adherence.
Goldman D.P., 2002 [16] - S.S. - Higher level of education was identified as a factor significantly 
associated with receiving HAART as a regimen and with higher level of 
adherence when using HAART.
Golin C.E., 2002 [14] S.S. S.S. N.S. Lower income and lower education were identified as independent 
factors significantly associated with lower level of adherence.
Singh N., 1999 [3] N.S. N.S. N.S. No SES components were significantly associated with adherence.
Kalichman S.C., 1999 [29] N.S. S.S. - Higher level of education and higher health literacy (among those with 
higher level of education) were identified as independent factors 
significantly associated with higher level of adherence.
Weiser S., 2003 [30] S.S. S.S. - Cost as a barrier to treatment was identified as an independent factor 
significantly associated with lower level of adherence (and gaps in 
treatment of otherwise would-be adherent patients). Incomplete 
secondary education was significantly associated with higher level of 
adherence.
Morse E.V., 1991 [21] S.S. N.S. - Receiving economic support by a 'significant other' was identified as an 
independent factor significantly associated with higher level of 
adherence.
Gebo K.A., 2003 [31] S.S. - - Running out of money for essentials during the previous 90 days was 
identified as an independent factor significantly associated with lower 
level of adherence.
Duong M., 2001 [32] - N.S. N.S. No SES components were significantly associated with adherence.
Ickovics J.R, 2002 [4] N.S. N.S. N.S. No SES components were significantly associated with adherence.
Singh N., 1996 [22] N.S. N.S. N.S. No SES components were significantly associated with adherence.
*S.S. = Statistically significant association found between SES component and adherence to treatment,
N.S. = No significant association found between SES component and adherence to treatment,
(-) = Association between SES component and adherence to treatment not examinedRetrovirology 2008, 5:13 http://www.retrovirology.com/content/5/1/13
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of behavioral characteristics and hierarchy at the decision-
making process, thus affecting their adherence to antiret-
roviral treatment [25]. Furthermore, perceived economic
support by a significant other was found to have a direct
association with levels of adherence to antiretroviral treat-
ment, in another of the reviewed studies [21]. Such find-
ings agree to the general idea linking stratification of
income to disparities in health status and the will to
adhere, placing the lower income patients on a depriva-
tion scope, while allowing for higher income patients to
adjust according to relative social status, possibly being
influenced by other SES factors such as education and
occupational status [13].
The existence of a possible association between level of
education and adherence to treatment in HIV/AIDS
patients was examined in 13 of the reviewed studies.
Among the 13 studies that considered education as a
probable factor affecting adherence to antiretroviral treat-
ment, only 4 original studies [14,16,24,29] proved a sta-
tistically significant positive association. Education,
providing the basis of a stable future for each person, as
well as altering the criteria used during the decision-mak-
ing process and the knowledge to access health resources
and information on disease and treatment, is a powerful
implement and could possibly be influenced by policies
targeted to enhance adherence among HIV patients
[5,6,16,29,33,34]. In 1 of the 4 studies, health literacy
among those highly educated was also associated with
higher level of adherence [29]. Health literacy is related to
educational level, but is influenced by other determinants
as well, such as health care providers' supportive manner
and instructional skills [33], should therefore be consid-
ered a sector in which external intervention – and further
training – is applicable [29,33,35]. Of note, in 1 of the 13
studies that examined the level of education, a statistically
significant reverse association between this variable and
adherence was found, although this interesting finding
was not elaborated further by the authors of the reviewed
study [30].
Employment status was either not assessed or not found
to be an independent factor associated with adherence, in
the majority of the studies that we reviewed. Specifically,
employment was found to have a significant impact on
adherence in only 1 of 8 studies that examined this factor.
The authors of that study postulated that having a busy
workload might be an impediment to the patients' ability
to adhere to antiretroviral treatment [15], therefore sug-
gesting an adverse association between adherence to
antiretroviral treatment and a demanding working sched-
ule. Unemployment and lower occupational status have,
however, been linked to lower levels of health status and
increased mortality [13] and could be blamed for lower
levels of adherence in terms of stress caused by job insecu-
rity, physical exhaustion, and lack of control over one's
working schedule (as was the case in the reviewed study)
[13,15], all of which could lead to a diminished intent
and/or capability to follow antiretroviral treatment
according to proper dosage and timetable [15]. We feel
that further research should be carried out in order to esti-
mate the possible effects of employment and occupa-
tional status on HIV patients' tendency to adhere to
antiretroviral treatment.
Our systematic review has several limitations. First, it was
not possible to make a synthesis of the data using the prin-
ciples of meta-analysis due to the fact that there was con-
siderable heterogeneity among the reviewed studies.
Adherence was measured by different methods in each of
the studies and the cutoff percentage of adherence to treat-
ment between 'adherent' and 'non-adherent' varied
among the studies, depending on the authors' estimate.
Furthermore, while most of the studies included patients
generally following the model of life prevailing in the
industrialized countries, some of the studies focused on
populations having special economic, cultural, and social
structures. Moreover, the studied patients received differ-
ent antiretroviral regimens, ranging from monotherapy to
HAART; the complexity of the treatment schedule affects
the level of a patient's adherence. Second, SES was not
focused upon as a homogenous group of specific factors
in any of the reviewed studies, but was rather dispersed
among its components, which were regarded as socio-
demographic information. Therefore, we were forced to
collect partial data regarding the association of such SES
components, and adherence to antiretroviral treatment,
where – and if – such an association was assessed. Occu-
pation was only assessed in terms of employment status,
as no data were given on status of occupation or working
position of the patients. Additionally, we could not ana-
lyze the possible association between other SES proxy var-
iables, such as the neighborhood, and adherence to
treatment because the included studies did not report rel-
evant data. Third, patients supposed to have lower SES, as
perceived by the treating physician, are generally more
likely to receive less complex antiretroviral regimens, and
more information on how to maintain a satisfying adher-
ence level. We cannot exclude that such an inequity could
have occurred in the reviewed studies, as most studies
were not set in a randomized controlled trial (RCT) envi-
ronment, and include random HIV patients, therefore
impeding our effort to find an association between levels
of SES, and adherence to antiretroviral treatment.
Adherence is a complex, dynamic process that influences
the outcome of HIV treatment and the patient's health sta-
tus [6,36]. It may change over time, as the health status or
the patients' beliefs and attitude regarding the disease, the
physician, and the treatment may alter, as well. As adher-Retrovirology 2008, 5:13 http://www.retrovirology.com/content/5/1/13
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ence does not concern only the patient, but the physician
and the public health system too, it becomes evident that
relevant factors cannot act independently, but instead
they all interrelate [1,6]. Lower level of adherence to
antiretroviral treatment leads to recurrence of the symp-
toms, drug resistance, and increases the patient's viral
load, thus affecting the patient-physician relationship in a
negative manner and creating possible hazards for the
community, in terms of transmission, viral resistance,
social stigma, and financial and/or management prob-
lems within the public health system [1-4]. Predicting
patients that are expected to have lower adherence, in an
objective manner, could establish an individual approach
to secure each patient's optimal response to antiretroviral
treatment, according to each patient's specific characteris-
tics [5,31].
On the other hand, it has been noted before that physi-
cians' choice regarding the medication they prescribe to
their HIV patients is often influenced by their own esti-
mates of expected level of patients' adherence to treat-
ment, based on social stereotypes [5]. In this way, HIV
patients with a low SES are less likely to be prescribed tri-
ple therapy [34,37]. However, the available evidence sug-
gests that such estimates on expected patient adherence
may have a limited accuracy and therefore should be
treated with caution as they can result in harmful clinical
consequences [30,36]. Also, the time the physicians
devote to their patients and the methods they use in order
to educate them about the HIV infection/disease, and con-
vince them about the importance of adhering to treat-
ment, depends on their judgments about the
sociodemographic characteristics of the patients [5,36]. It
is obvious that such an inequity in attention and instruc-
tions given by the physician, perhaps unavoidable in
every day practice where patients gather in great numbers
and time remains limited, results in uneven levels of co-
operation and adherence between different patients.
Unlike SES, there were other factors, which were found to
influence greatly and consistently HIV patients' adherence
in the reviewed studies. Specifically, psychosocial factors
such as depression [22,24,26,28,31], active drug
[14,22,24,26,31] or alcohol use [14,26], and lack of social
support and stability were associated with suboptimal
level of adherence [2,3,5,8,21]. Furthermore, cognitive
factors such as self-efficacy and patients' beliefs and views
regarding the disease and the effectiveness of medication
(outcome expectancies) were found to be significant
determinants of adherence [3,4,14,27,32,38]. Also,
adverse events were associated with lower level of adher-
ence [4,8,30]. In general, complex schedule of drug ther-
apy along with food restrictions were assessed as primary
barriers to medication adherence [5,6,8,9,14,21,25,27].
The quality of the patient-physician relationship played
an important role as well. Acceptance, open communica-
tion, cooperation and trust in physicians were reported to
be strong predictors of enhanced adherence [1,2,5,6,21].
In several studies it has been shown that SES is signifi-
cantly associated with adherence to treatment in patients
with chronic diseases [10-12]. Despite the fact that HIV
infection is included among chronic diseases, it differs
from all others. This is probably due to the fact that this
infection is socially stigmatized, in grounds of transmis-
sion. It is not only a physical disease, but a psychological,
mental, and social, too. In addition, this infection is con-
nected with social discrimination, guilt, and prejudice
[5,28,30]. HIV infection is a life-changing event, affecting
the psychological status of the patient and results in his/
her having to adjust again, in new conditions of life. It
seems that during this process, cognitive and psychologi-
cal factors are more important than SES for adherence to
therapy.
In order for HIV patients to achieve higher levels of adher-
ence to treatment, interventions regarding the patient, the
clinician and the treatment have to be made [5,6]. Specif-
ically, helping patients to understand more about the HIV
infection, as well as the antiretroviral treatment
[5,6,16,29,33-35], coping with co-existing behavioral or
psychiatric diseases [1,3,5,6], and adjust medication
schedules to the patients daily program or using memory
helpers such as special pillboxes, reminders etc.
[5,6,14,15] are all important strategies. Additionally, the
physician being consistent, vigilant, available, and
explanatory can motivate the patient to adhere more to
the antiretroviral treatment [1,38]. Warning the patients
about potential side effects and coping with them timely,
checking the list of medications at each visit, giving writ-
ten information or showing pictures so as to provide
instructions, are alternative and effective ways to ensure
patients co-operation and participation in the therapeutic
process [5,6,34]. As for the health system, it has to be
noted that having a medical insurance and easy access to
primary care, receiving treatment by the same medical
providers each time, receiving counseling by specialists,
and not having to pay for the antiretroviral regimens, are
factors that enhance adherence level [2,4,5,9,21,30].
Improving a patient's financial and educational back-
ground is sometimes an impossible mission, however the
aforementioned policies on educating and supporting the
HIV patient can result in better adherence levels and
should be investigated further, in terms of effectiveness.
Conclusively, the available evidence suggests that SES is
not consistently associated with adherence to therapy
among patients infected with HIV and it does not seem to
be a major determinant of adherence to antiretroviral
treatment. Many available studies suggest a positive trendRetrovirology 2008, 5:13 http://www.retrovirology.com/content/5/1/13
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among factors contributing to patients' SES and adher-
ence to medical treatment among patients with HIV/
AIDS, however such an association cannot be statistically
consolidated throughout most of the studies included in
our systematic review. It should be emphasized that it
appears that there is a confusion regarding the accurate
meaning of the term "SES" and thus it has been assessed
in various ways. Future studies may further explain the
different impact of SES to adherence to treatment between
patients infected with HIV and patients suffering from
other chronic diseases.
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